What is Leqmbi? The first Alzheimer’s treatment was approved in Saudi Arabia today. world News
Saudi Food and Drug Authority (SFDA) today announced the official approval of Alzheimer’s treatment, Leqmbi available in Saudi Arabia today. This approval is an important milestone in addressing Alzheimer’s, a progressive brain disorder that affects memory and thinking skills. Leqmbi is indicated for patients who experience mild cognitive loss or mild dementia, especially by Alzheimer’s, who have either no copies or have just one copy of a particular gene variant known as apolipoprotein E4.
How to Work Lequembi: Target the Rotable Reason
Lequmbi represents an innovative approach to the treatment of Alzheimer’s. Unlike many existing treatments that reduce only symptoms, the purpose of this drug is to slow down the actual progress of the disease. It is a biologic therapy developed using a monoclonal antibody technique, a sophisticated method that forms laboratory-produced molecules designed to target specific proteins in the body. In this case, Leqmbi works by targeting beta-amyloid proteins, which form in the brain of Alzheimer’s patients and form a sticky clump called plaque. These plaques are widely contributed to cognitive decline seen in the disease. In particular, the plaques of the brain, known as amyloid plaques, are unusual clumps of protein pieces, called beta-amyloids that form in the brain, especially in people with Alzheimer’s. These planets interfere with normal communication between nerve cells (neurons), inhibiting brain function. By helping reduce the formation of these harmful plaque, LeQambi wants to protect brain function and slow cognitive decline over time. Treatment is given through an intravenous infusion every two weeks, allowing the drug to transmit and function within the brain.
Effectiveness supported by clinical studies
Before approved the Lequembi, SFDA thoroughly reviewed its safety, effectiveness, quality and evidence of compliance with regulatory standards. Clinical trials showed that Lequmbi significantly slows down the progression of Alzheimer’s disease compared to a placebo. The effectiveness was measured using installed clinical parameters that assess memory, thinking and daily functioning capabilities. However, like all drugs, lequembi can cause side effects. Most reported reported:
- Headache
- Reactions related to infusion process
- Amyloid-related imaging abnormalities (ARIA), a term that refers to abnormal changes found in brain MRI scans. These abnormalities may include inflammation (cerebral edema) or small brain bleeds (microemorase).
Because Aria can only be detected through the brain scan, careful monitoring is necessary throughout the treatment.
Security first: required careful monitoring of the patient
The SFDA emphasizes the importance of monitoring the patient running during treatment. Before starting the lequembi, patients should be tested for their Apee4 gene position, as it affects the risk of side effects. People with two copies of Apoe4 genes are not currently eligible for treatment due to the greater possibility of complications. Additionally, the pharmaceutical company responsible for Lequmbi needs to track how the drug performs in (post-marketing monitoring) once used. They must regularly submit an updated report on safety and effectiveness to SFDA. The use of treatment is also mandatory to safely and ensure that a comprehensive risk management plan is also mandatory.
Power healthcare with Biotechnology in Saudi Arabia
Leqmbi’s approval reflects SFDA’s commitment to expand access to advanced and high quality medical remedies, especially those who have been developed through state-of-the-art biotechnical methods. Biotech therapy, such as Leqmbi, represent the rapidly growing area in the drug, provides new hope for diseases that were previously limited treatment options.
About SFDA
Established under the resolution of the Council of Ministers in 2003, the Saudi Food and Drug Authority is an independent regulatory body that reports directly to the Chairman of the Council. Its main mission is to protect public health by ensuring food, drugs, biological and chemical substances, medical devices and cosmetics. SFDA oversees all processes related to these products, aimed at protecting both human and animal health throughout the state.
